Back to News
Market Impact: 0.65

Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics

DXCMNVDASPY
Corporate EarningsCompany FundamentalsAnalyst EstimatesHealthcare & BiotechTechnology & InnovationAnalyst Insights
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics

DexCom (DXCM) reported robust Q2 2025 results, with revenue climbing 15.2% year-over-year to $1.16 billion, exceeding the Zacks Consensus Estimate of $1.12 billion by 3.06%. Earnings per share also beat expectations, reaching $0.48 compared to a $0.45 consensus, marking a 6.67% surprise from the prior year's $0.43. The company's stock has outperformed the broader market, returning +6.9% over the past month against the S&P 500's +3.4%, and holds a Zacks Rank #2 (Buy).

Analysis

DexCom (DXCM) delivered a robust financial performance in its second quarter of 2025, exceeding Wall Street expectations on both top and bottom lines. The company reported total revenue of $1.16 billion, a 15.2% year-over-year increase that surpassed the consensus estimate by 3.06%. Similarly, earnings per share came in at $0.48, representing a 6.67% surprise above the projected $0.45. This growth was primarily fueled by the core "Sensor and other" segment, which saw revenue climb 18% to $1.12 billion, also beating forecasts. Geographically, the performance was broad-based with U.S. revenue growing 14.9% and International revenue up 16%, both exceeding analyst estimates. A notable counter-trend was the significant 31.4% year-over-year decline in Hardware revenue, which fell to $39.3 million, although this figure narrowly beat its specific consensus estimate. The stock's recent performance reflects this positive operational momentum, having returned +6.9% over the past month, outperforming the S&P 500 composite's +3.4% gain, and currently holds a Zacks Rank #2 (Buy).

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo